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Abstract: Nowadays, aspirin (acetylsalicylic acid) and clopidogrel form the cornerstone in pre-
vention of cardiovascular events and their clinical effectiveness has been well established. The thi-
enopyridine clopidogrel is a prodrug that, after hepatic metabolization, strongly inhibits adenosine 
diphosphate-induced platelet aggregation. Aspirin is a non-steroidal anti-inflammatory drug 
that exerts its anti-platelet action through the irreversible acetylation of platelet cyclooxygenase 
(COX)-1, blocking thromboxane A2 production. However, despite dual-antiplatelet therapy, 
some patients still develop recurrent cardiovascular ischemic events. Many studies have clearly 
showed that a marked variability exists in the responsiveness to aspirin and clopidogrel, being 
the poor responder patients at higher risk of short (peri-procedural) and long-term ischemic 
complications. In particular, these patients showed a major recurrence of myocardial infarction 
and, after stent implantation, of stent thrombosis. The mechanisms of aspirin and clopidogrel 
poor response are numerous and not fully elucidated, and are likely multifactorial (eg, genetic 
polymorphisms, elevated baseline platelet reactivity, drug interaction). How to improve the 
short- and long-term outcome of these patients is currently unknown. Recently published and 
ongoing clinical trials are evaluating different strategies for the acute and chronic treatments 
(eg, reload of clopidogrel, double clopidogrel maintenance dose, switching to prasugrel). In 
this paper, we reviewed all available evidence on aspirin and clopidogrel resistance and focused 
our attention on tirofiban, a glycoprotein IIb/IIIa inhibitor that may be used to obtain a better 
platelet inhibition in poor responder patients during the acute phase and in particular during 
percutaneous coronary intervention.
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Introduction
Cardiovascular diseases are the most common cause of mortality and morbidity 
in western countries in the 21st century. Because aggregation of platelets highly 
  contributes to the development of cardiovascular events, inhibition of this process 
plays an important role in the prevention of cardiovascular disease. Nowadays, 
aspirin (acetylsalicylic acid) and clopidogrel form the cornerstone in secondary 
  prevention of cardiovascular events. The clinical effectiveness of aspirin on the preven-
tion of cardiovascular events has been well established. The Antithrombotic Trialists’ 
  Collaboration has documented in their most recent meta-analysis of 287 randomized 
trials, incorporating more than 200000 patients, a 22% reduction of death and serious 
ischemic vascular events by antiplatelet therapy with aspirin compared with placebo.1 Journal of Blood Medicine 2010:1 62
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Similarly, many randomized clinical trials (eg, CAPRIE,2 
CURE,3 PCI-CURE,4 CREDO5) have shown the clinical 
effectiveness and utility of long-term clopidogrel treatment 
(alone or in association with aspirin) in reducing the com-
bined risk of ischemic stroke, myocardial infarction (MI), 
and vascular death. However, not all patients profit to the 
same extent, which could be explained by a variety of phar-
macodynamic, pharmacokinetic, and biochemical features. 
Addressed biochemically as persistent platelet reactivity in 
vitro despite use of aspirin and/or clopidogrel, this phenom-
enon is called ‘resistance’ or ‘poor responsiveness’ to oral 
antiplatelet agents (OAA; aspirin and clopidogrel), although 
a uniform definition is lacking.
In this paper, we reviewed all available evidence on 
aspirin and clopidogrel resistance and focused our attention 
on tirofiban, a glycoprotein IIb/IIIa inhibitor, which may be 
used to obtain a better platelet inhibition in poor responder 
patients during the acute phase and so overcome the higher 
risk of ischemic complications of these patients.
Poor response to clopidogrel
The thienopyridine clopidogrel is a prodrug that needs 
to be metabolized to an active compound that is a potent 
  inhibitor of ADP induced platelet aggregation. ADP is 
a platelet activator that is secreted from platelets upon 
activation and is released from damaged vessels and red 
blood cells. Three ADP receptors have been described on 
platelets. P2X1 (a calcium channel), P2Y1 (coupled to 
Gq that mobilize intracellular calcium) and P2Y12, which 
leads to inhibition of adenylate cyclase via Gi-protein. The 
P2Y12 receptor has been identified as a target of clopidogrel 
(Table 1). More specifically, clopidogrel is oxidized in a 
cytochrome P450 (CYP) mono-oxygenase dependent way to 
2-oxo-clopidogrel, an intermediate metabolite that is further 
hydrolyzed to the active thiol metabolite of clopidogrel. The 
active metabolite irreversibly binds to the P2Y12 receptor 
(Figure 1). Although CYP3A4 is not the only cytochrome 
P450 isoenzyme involved in the metabolism of clopidogrel, 
it is quantitatively the most important one. The major 
circulating metabolite of clopidogrel is a carboxylic acid 
derivate that completely lacks of anti-aggregation activity. 
There is growing evidence suggesting that the response to 
clopidogrel shows an important interindividual variability6 
and that may be influenced by pharmacokinetic variables 
such as intestinal absorption and metabolic activation in the 
liver, both of which are affected by genetic polymorphisms.7 
In particular, previous studies clearly showed that a valu-
able group of patients has lower levels of clopidogrel active 
metabolite, diminished platelet inhibition, and higher rates 
of adverse cardiovascular events.8 Nowadays different assays 
are available to evaluate the clopidogrel induced platelet 
inhibition (clopidogrel response). The most used are light 
transmission aggregometry, VerifyNow, Multiplate Analyzer, 
and VASP index. Independently to the assay and the cut-off 
Table 1 Principal characteristics of clopidogrel, aspirin and tirofiban
Clopidogrel Aspirin Tirofiban
Characteristics
Compound
 
Thienopyridine  
(second generation)
 
Non-steroidal  
anti-inflammatory drug
 
Peptidomimetic nonpeptide
Mechanism of action Irreversible and selective  
antagonism of adenosine  
diphosphate receptor,  
subtype P2Y12
Irreversible acetylation of  
platelet cyclooxygenase  
(COX)-1
Competitive inhibitor of GP IIb/IIIa 
platelet receptor
Way of administration per os per os intravenous
Reversibility of effects 5–8 days 8–10 days 4 hours
Platelet bound half life 4–5 days 10 days 11 s
Plasma half life 6 hours 15–20 min 1.8 h
Dose Loading dose:  
300 or 600 mg (600 mg preferably)  
Maintenace dose:  
75 mg/die
Loading dose:  
150–325 mg  
Maintenace dose:  
75–160 mg/die
PRISM-PLUS dose (upstream therapy):  
0.4 µg/kg/min for 30 minutes + infusion 
0.1 µg/kg/min  
Restore dose:  
10 µg/kg bolus + infusion 0.15 µg/kg/min   
Single high dose bolus (downstream 
therapy):  
25 µg/kg bolus + infusion 0.15 µg/kg/min
Clearance Renal 50%, fecal 50% Renal Renal (60%–70%), biliar (20%–30%)Journal of Blood Medicine 2010:1 63
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used, a strong association between clopidogrel response and 
adverse events has been observed. For example, using light 
  transmission aggregometry, in the CREST (Clopidogrel 
Effect on Platelet Reactivity in Patients With Stent Throm-
bosis) study a relationship between high post-treatment 
platelet reactivity, incomplete P2Y12 receptor inhibition 
and sub acute stent thrombosis has been found,9 whereas in 
the EXCELSIOR study (Impact of Extent of Clopidogrel-
Induced Platelet Inhibition During Elective Stent Implan-
tation on Clinical Event Rate) relatively low-risk patients 
undergoing percutaneous coronary intervention (PCI) at least 
2 hours after 600 mg loading dose of clopidogrel had higher 
risk of death, reinfarction, and stent thrombosis at 30 days.10 
Marcucci et al showed that on-treatment residual platelet 
reactivity, measured by the point-of-care assay VerifyNow 
P2Y12, is able to detect acute coronary syndrome patients 
at risk of 12-month cardiovascular death and nonfatal MI, 
founding, as optimal cutoff, the value of 240 P2Y12 reaction 
units.11 Using the same instrument and the same cutoff, Patti 
et al demonstrated that patients with high platelet reactivity 
during clopidogrel treatment (after 600 mg loading dose) 
had higher risk of peri-procedural MI.12 Similarly in the 
study leaded by Sibbing et al using Multiplate Analyzer, has 
been found that clopidogrel poor responders, as compared to 
patients with a normal response, had a significantly higher 
risk of definite stent thrombosis (2.2% vs 0.2%; P  0.01) 
and mortality (1.2% vs 0.4%; P = 0.07) within 30 days.13
Poor response to aspirin
Aspirin is a non steroidal anti-inflammatory drug that is 
quickly absorbed by gastrointestinal mucosa, and has a hepatic 
metabolism (Table 1 and Figure 1). Aspirin, or acetylsalicylic 
acid, exerts its anti-platelet action through the irreversible 
acetylation of platelet cyclooxygenase (COX)-1 at serine 
residue 530 (Figure 1). This enzyme is responsible for con-
version of arachidonic acid to the various eicosanoids, such 
as leukotrienes, prostaglandins, thromboxane A2 (TXA2), and 
prostacyclin, or prostaglandin I2 (PGI2). Thromboxane A2 
is a potent vasoconstrictor and platelet agonist found in the 
α-granules of the platelet, which are released during platelet 
activation. Production of TXA2 has been completely inhibited 
by doses of aspirin as low as 100 mg. Despite several studies 
Arachidonic
acid Acetylation
Cox-1
PGG2 PGH2
ASA
ASA Salicylate
PGI1 TXA2
Clopidogrel
(prodrug)
Intestinal absorption
(ABCB1)
Hepatic metabolism
(CYP3A4, CYP3A5,
CYP2C19)
Esterases Inactive metabolites
(85% of clopidogrel
dose)
Active metabolites
(15% of clopidogrel dose)
P2RY12 receptor
On platelet surface  ADP GPIIb/IIIa
receptor
CLOPIDOGREL
MECHANISM OF
ACTION OF ORAL
ANTIPLATELET
AGENTS
Figure 1 Mechanisms of action of aspirin and clopidogrel.
Abbreviations: ASA, aspirin; Cox, cyclo-oxygenase; PG, prostaglandin; Tx, thromboxane; ADP, adenosine diphosphate.Journal of Blood Medicine 2010:1 64
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published on ‘aspirin resistance’, its definition, diagnosis, 
prevalence, causes, and clinical consequences are still uncer-
tain.14 Direct comparison of different laboratory methods to 
detect aspirin resistance usually showed very weak or no 
correlation, indicating that they are sensitive to different 
parameters. In addition, the calculated prevalence of aspirin 
resistance in 11 studies that used different functional assays 
of platelet function, varied between 5.5% and 61%.15 Studies 
that measured TxB2 levels in aspirin-treated patients reported 
a prevalence of aspirin resistance that ranged between 1% 
and 1.7%.16 Therefore, aspirin resistance, when tested with 
  appropriate, specific tests, appears to be extremely rare, and, 
in most instances, due to under-dosing or non-compliance. 
Nevertheless, several authors have found a good associa-
tion between aspirin poor response and adverse events. For 
example, Eikelboom et al showed that suboptimal reduction 
of urinary 11-dehydro TxB2 levels during aspirin treatment is 
associated with heightened risk of future myocardial infarction 
and cardiovascular death.17 Similarly Gum et al found, in a 
cohort of 326 patients, 17 aspirin poor responders and 4 of 
these (24%) experienced death, MI, or cerebrovascular acci-
dent, as compared with 30 of 309 (10%) patients who were 
aspirin full responders (P = 0.03).18 Aspirin poor response 
emerged also at multivariable analyses as independent predic-
tor. Finally, Chen et al showed that, in patients undergoing PCI, 
aspirin poor response, as evaluated by VerifyNow instrument, 
is associated with an higher incidence of cardiovascular death, 
myocardial infarction, stroke, and transient ischemic attack, in 
particular due to higher occurrence of peri-procedural MI.19
Mechanism of antiplatelet 
resistance or variable response 
to oral antiplatelet agents
The mechanisms of aspirin and clopidogrel poor response 
are numerous and not fully elucidated, and are likely to 
be multifactorial (Table 2). Below we have reported and 
  discussed the most important.
Genetic polymorphisms
Previous studies have clearly identified different gene 
  polymorphisms modulating clopidogrel absorption 
(eg, ABCB117), metabolic activation (eg, CYP3A519 
and CYP2C19) and biologic activity (eg, P2RY1214 and 
ITGB311).7,8 Specifically, common polymorphisms in the 
CYP2C19 gene, seen in approximately 30% of whites, 40% 
of blacks, and more than 55% of east Asians, significantly 
diminish both the pharmacokinetic and pharmacodynamic 
responses to clopidogrel by approximately one quarter to 
one third. In particular, CYP2C19*2 is the most frequent 
variant allele (95%) among the reduced-function group. This 
loss-of-function variant encodes a cryptic splice variant that 
leads to no enzymatic activity. Among clopidogrel-treated 
subjects in TRITON–TIMI 38, carriers of a reduced-function 
CYP2C19 allele had a relative increase of 53% in the 
  composite primary efficacy outcome of risk of death from 
cardiovascular causes, myocardial infarction, or stroke, as 
compared with non carriers (12.1% vs 8.0%; hazard ratio 
for carriers, 1.53; 95% CI, 1.07 to 2.19; P = 0.01), and an 
Table 2 Mechanisms of clopidogrel and aspirin poor response
Clopidogrel Aspirin
Relevance Relevance
Polymorphisms of CYP3A4  
(lower activation)
♦ ♦ ♦ ♦ Lack of compliance ♦ ♦ ♦ ♦
Polymorphisms of CYP2C19  
(lower activation)
♦ ♦ ♦ ♦ Accelerated platelet turnover ♦ ♦ ♦
Poor compliance ♦ ♦ ♦ ♦ Poor absorption ♦ ♦ ♦
Underdosing ♦ ♦ ♦ ♦ Presence of COX-1 variants ♦ ♦
Elevated platelet basal reactivity ♦ ♦ ♦ ♦ TxA2 production by the aspirin-insensitive  
COX-2 isoform
♦ ♦
Accelerated platelet turnover ♦ ♦ ♦ Interference with other drugs ♦ ♦
Interference with other drugs ♦ ♦
Polymorphisms of P2Y12 receptor ♦ ♦
Upregulation of the P2Y1 pathway ♦ ♦
Upregulation of P2Y-independent  
pathway (collagen, thromboxane  
A2, thrombin)
♦ ♦
Insufficient intestinal absorbtion ♦ ♦Journal of Blood Medicine 2010:1 65
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increase by a factor of 3 in the risk of stent thrombosis 
(2.6% vs 0.8%; hazard ratio, 3.09; 95% CI, 1.19 to 8.00; 
P = 0.02).8
Interferences with other drugs
Attention has been placed on a potential interaction observed 
between clopidogrel and the widely used proton pump 
  inhibitors (PPIs). The CYP2C19 isoform is the key enzyme 
in the metabolism of many of the PPIs, which are also 
inhibitors of the CYP2C19 isoenzyme in varying degrees. 
In addition to metabolic inconsistencies, variability of intes-
tinal absorption is also an important determinant of the wide 
response variability to clopidogrel. PPIs are substrates and 
inhibitors of the intestinal efflux transporter P-glycoprotein, 
a key factor for intestinal absorption of clopidogrel. Never-
theless, in a large population of patients with acute coronary 
syndrome undergoing percutaneous coronary intervention, 
the use of a PPI was not independently associated with 
increased risk of adverse clinical outcomes for patients 
treated with either clopidogrel or the novel thienopyridine 
prasugrel.20 As a contrary, an important competition of aspi-
rin with other non steroidal anti-inflammatories (NSAIDs), 
such as ibuprofen, has been clearly reported. Ibiprofen 
can prevent aspirin access at Ser530 of COX-1 and, as a 
consequence, its irreversible acetylation and inactivation 
of the enzyme.
Elevated baseline platelet reactivity
In vitro data suggest that diabetes mellitus and acute coronary 
syndromes (ACS) may be associated with increased platelet 
reactivity.21,22 Many studies showed that patients with 
diabetes or presenting with ACS have larger platelets, an 
increased number of GP IIb/IIIa receptors on each platelet, 
and an increased population of activated circulating 
  platelets, expressing, among other substances, P-selectin 
and thrombospondin. These adhesion molecules mediate 
platelet-leukocyte interactions and therefore are potential 
triggers of inflammatory response and thrombosis. In this 
specific subset we observed higher baseline platelet reactivity 
and, as consequence, both aspirin and clopidogrel effects 
are lower, and more time and higher dose are necessaries to 
obtain a significant platelet inhibition.21–23
Accelerated platelet turnover
An accelerated platelet turnover could be involved in the 
poor response to aspirin. It may introduce newly formed, 
non-aspirinated platelets into the blood stream, which are 
able to form TxA2.23
Tirofiban
The glycoprotein (GP) IIb/IIIa inhibitors are potent 
  antagonists of platelet aggregation that are approved to 
prevent thrombotic complications of PCI and as medical 
treatment of patients with acute coronary syndromes (ACS). 
Tirofiban is a small synthetic nonpeptide, competitive 
GPIIb/IIIa inhibitor with high specificity and affinity 
for GPIIb/IIIa receptors conferred by a tyrosine analog 
  structurally similar to the RGD (arginine-glycine-aspartic 
acid)-loop of the GPIIb/IIIa receptor.24 Tirofiban is 
  administered as an intravenous infusion and approximately 
35% is unbound in the circulation with predominant renal 
clearance (65%), and it can be hemodialyzed (Table 1). 
Renal function may influence the excretion of tirofiban, but 
concurrent disease or other drugs generally used in patients 
with ischemia seem not to do so.
Clinical efficacy of tirofiban
Tirofiban has been tested both in patients with ACS, admin-
istered soon after hospital admission as part of the medical 
therapy, and in high-risk patients, including, but not limited to, 
those presenting with acute coronary disorders, administered 
immediately before PCI. In the PRISM (Platelet Receptor 
Inhibition for ischemic Syndrome Management) study, a total 
of 3231 patients presenting with ischemic symptoms of 
unstable angina were randomized to tirofiban or unfractioned 
heparin (UFH).25 In this trial the incidence of the primary 
composite endpoint (death, myocardial infarction, or refrac-
tory ischemia) at 48 hours was 32% lower in the group that 
received tirofiban (P = 0.01) and, at 30 days, the mortality 
was 2.3% in the tirofiban arm and 3.6% in the heparin group 
(P = 0.02). Major bleeding occurred in 0.4% of patients in both 
groups.25 In the PRISM-PLUS trial a total of 1915 patients 
with high-risk non ST-segment elevation ACS were enrolled 
to evaluate tirofiban plus adjusted dose heparin, or adjusted 
dose heparin alone.26 The frequency of the composite primary 
endpoint at 7 days was lower among the patients who received 
tirofiban, in particular there was a 47% decrease in the risk of 
MI (P = 0.006) and a 30% decrease in the risk of refractory 
ischemia (P = 0.02) as compared with the risk in the heparin-
only group. The risk of the composite endpoint of death or MI 
was reduced by 43% (P = 0.006).26 Similarly, the RESTORE 
trial found a reduction in the incidence of composite end-
point (death, MI, coronary artery bypass graft, target vessel 
revascularization) at 2 (P = 0.005) and 7 days (P = 0.02) in 
the tirofiban group and a non statistically significant reduction 
of the endpoints at 30 days (from 12.2% in placebo group to 
10.3% in tirofiban group P = 0.160).27Journal of Blood Medicine 2010:1 66
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Safety and tolerability of tirofiban
The most serious and frequent adverse effects related to 
the use of GPIIb/IIIa receptor antagonists are bleeding and 
thrombocytopenia. Risk of bleeding can be reduced by the 
use of low-dose adjunctive heparin, early sheath removal, and 
meticulous post-procedure care. In studies involving tirofiban, 
the incidence of bleeding complications was more frequent 
than heparin alone, but major bleeding complications were 
not significantly different. Most of the increases in bleeding 
occurred in patients who underwent diagnostic catheteriza-
tion or PCI, primarily at the femoral artery access site. The 
incidence of thrombocytopenia, defined as an absolute platelet 
count of less than 90,000/mm3, was 0.4% in PRISM and 
PRISM-PLUS trials.25,26 Finally in the Single High Dose Bolus 
Tirofiban and Sirolimus Eluting Stent in Myocardial Infarction 
(STRATEGY) trial, the use of tirofiban was associated with a 
trend towards reduction of any bleeding and to a statistically 
significant reduction in the incidence of thrombocytopenia 
(P = 0.03) compared with abciximab.28
Single high dose bolus tirofiban
Tirofiban administration was shown to significantly 
reduce mortality, the composite of death or MI along 
with major adverse cardiovascular events (MACE) rate 
when compared with placebo.25–27 This benefit in ischemic 
  endpoints reduction remained significant and of consistent 
magnitude in studies where tirofiban was tested in addition 
to thienopyridines but came at an increase risk for minor 
bleeding and thrombocytopenia.29 An early ischemic hazard 
  disfavouring tirofiban was noted when compared with 
  abciximab in studies based on 10 mg/kg bolus regimen.30 
Indeed, in the TARGET study tirofiban (RESTORE 
  regimen, 10 µg/kg bolus +0.15 µg/kg/min infusion) was 
tested vs abciximab in moderate-high risk patients under-
going PCI and the primary endpoint (composite of death, 
nonfatal MI, and urgent target vessel revascularization 
within 30 days after procedure) occurred more frequently 
in the tirofiban group than in the abciximab group (7.6% 
vs 6%, P = 0.03).30 The superiority of abciximab was 
entirely driven by a higher rate of peri-procedural MI in 
the tirofiban arm. Tirofiban administrated immediately 
before PCI at RESTORE regimen was not sufficient and, 
as compared with abciximab, provided an inferior degree 
of platelet inhibition. As a consequence of the suboptimal 
platelet inhibition achieved, subsequent dose-ranging stud-
ies have led to an increase in the tirofiban bolus dose from 
10 to 25 µg/kg. The new single high dose bolus (SHDB) 
of tirofiban achieves an average inhibition of platelet 
  aggregation of more than 90% throughout the first hour after 
treatment, which was shown to be comparable with that of 
abciximab. Subsequently, many studies have confirmed the 
safety and efficacy of SHDB tirofiban (eg, ADVANCE,31 
STRATEGY,28 MULTISTRATEGY,32 FATA33 trials). The 
ADVANCE study included patients undergoing high-risk 
PCI, being or patients with diabetes and/or ACS or subjected 
to planned multivessel PCI. All patients were at steady-state 
for aspirin and thienopyridine and were randomized before 
PCI to SHDB tirofiban vs placebo. Tirofiban administration 
was able to reduce significantly myocardial infarction rate 
and GPIIb/IIIa bailout use.31 As a contrary, the STRATEGY 
and MULTISTRATEGY studies included patients with 
  ST-segment elevation myocardial infarction. One of the 
aims of these studies was the comparison between SHDB 
tirofiban and abciximab, the GPIIb/IIIa inhibitor gold stan-
dard during primary PCI. No significant differences were 
found between tirofiban and abciximab (surrogate endpoint: 
ST-segment resolution 50% after primary PCI).28,32
Tirofiban and daily clinical practice
In conclusion, when used in high-risk patients, adjunctive 
tirofiban therapy, compared with placebo, is associated with a 
≈30% reduction in all considered ischemic endpoints includ-
ing overall mortality, mortality or MI, and MACE rates within 
30 days after treatment. Importantly, the benefit observed soon 
after intervention persisted at the longest available follow-up. 
As expected, the advantage in terms of ischemic endpoints was 
counterbalanced by a significant increase in minor, but not 
major, bleeding and thrombocytopenia.29 When employed just 
prior to PCI, an early ischemic hazard disfavoring tirofiban 
was noted as compared with abciximab in studies based on 
10 mg/kg bolus,27 whereas tirofiban at SHDB regimen may 
provide similar efficacy yet an improved safety profile.29
Use of GPIIb/IIIa inhibitors  
to overcome poor response  
to OAA during PCI
The data indicating that low response to clopidogrel carries 
clinical significance are stronger than the data for aspirin. 
Nevertheless, several studies have clearly reported that 
aspirin and clopidogrel poor responders are at higher risk of 
peri-procedural MI,12,19 and that it is a known independent 
predictor of worse long-term clinical outcome. It is important 
to note that the risk carried by aspirin and/or clopidogrel poor 
response is higher and more frequent in high-risk patients, but 
it is present and significant also in low risk patients (eg, PCI for Journal of Blood Medicine 2010:1 67
Tirofiban in poor responders to aspirin and/or clopidogrel Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
stable angina or silent ischemia or low-risk ACS). Nowadays, 
clinical approaches to overcome low response to aspirin or 
clopidogrel have not been established or examined system-
atically with randomized clinical trials. An initial approach 
would be to correct clinical factors that may contribute to low 
response or to decrease drug-drug interactions (eg, between 
aspirin and non-steroidal anti-inflammatory drugs or clopi-
dogrel and proton pump inhibitors).
Another interesting strategy could be the tailored use 
of GPIIb/IIIa inhibitors in poor responder patients during 
PCI. This approach has been tested in two recent studies. 
Firstly, Cuisset et al have investigated the benefit of adjusted 
antiplatelet therapy with GPIIb/IIIa inhibitors (abciximab) 
in clopidogrel poor responders (using LTA to assess the 
drug response).34 In this study, a patient was considered 
poor responder whether platelet aggregation during aspirin 
and clopidogrel therapy at steady-state was 70%. 149 
clopidogrel poor responders referred for elective PCI were 
included and randomized to ‘conventional group’ or ‘active 
group’ with GPIIb/IIIa inhibitors. The rate of cardiovascular 
events at 1 month was significantly lower in the ‘active group’ 
than in the ‘conventional group’ (19% vs 40% respectively, 
P = 0.006).34 As a contrast, in the Tailoring Treatment With 
Tirofiban in Patients Showing Resistance to Aspirin and or 
Resistance to Clopidogrel (3T2R) study Valgimigli et al had 
screened 1277 patients to enrol 93 aspirin, 147 clopidogrel, and 
23 dual poor responders (totally 263 poor responder patients 
randomized), who underwent elective PCI for stable or low-
risk unstable coronary artery disease.35 According to current 
guidelines, this subset of patients should be treated only with 
aspirin, clopidogrel, and unfractioned heparin bolus during the 
PCI procedure. The VerifyNow System was used to evaluate 
both aspirin and clopidogrel response. A patient was defined 
aspirin poor responder when ARU value was 550; whereas 
a patient was considered clopidogrel poor responder when 
platelet inhibition by clopidogrel was 40%. Poor responders 
were randomly assigned in a double-blind manner to receive 
either SHDB tirofiban or placebo on top of standard aspirin 
and clopidogrel therapy. The primary endpoint was the rate of 
peri-procedural MI defined as an elevation of troponin I/T ratio 
3 times the upper limit of normal (ULN) within 48 hours 
after completion of the PCI according to the recent universal 
definition of MI. The study showed that triple antiplatelet 
therapy, including a tailored infusion of tirofiban, in patients 
who responded poorly to aspirin, clopidogrel, or both, resulted 
in a ≈40% reduction in the incidence of periprocedural MI 
compared with standard care.35 The early benefit, in terms of 
peri-procedural MI, was largely maintained at 30 days, with the 
cumulative incidence of major adverse cardiovascular events 
reduced in the tirofiban group (Figure 2). Of note, no increase 
Placebo Tirofiban
P = 0.009
P = 0.08
P = 0.03
(%)
Peri-procedural MI
(3× troponin)
Peri-procedural MI
(3× CKMB)
MACE
(death, MI, urgent TVR)
40
35
30
25
20
15
10
5
0
Figure 2 Principal endpoints in 3T/2R study.
Abbreviations: MI, myocardial infarction; MACE, major adverse cardiovascular events; MI in the mace count was defined as creatin-kinase MB (CKMB) 3x elevation upper 
normal limit; TVR, target vessel revascularization.Journal of Blood Medicine 2010:1 68
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in the risk of bleeding events was observed in the group of 
patients receiving tirofiban.35
Conclusion
Dual-antiplatelet therapy with aspirin and clopidogrel 
  significantly reduces atherothrombotic events and improves 
long-term clinical outcomes in patients undergoing PCI and/or 
with ACS. However, despite dual-antiplatelet therapy, some 
patients still develop recurrent cardiovascular ischemic events. 
Many studies have clearly showed that a marked variability 
exists in the responsiveness to aspirin and clopidogrel, being 
the poor responder patients at higher risk of short- (peri-proce-
dural) and long-term ischemic complications. Ongoing studies 
and new available antiplatelet drugs may permit to optimize 
their management and to improve their clinical outcome. 
Accordingly, the 3T/2R study showed that a tailored use of 
SHDB tirofiban in patients undergoing PCI, clinically at low-
risk being stable patients, but biologically at high-risk being 
aspirin and/or clopidogrel poor responders, is safe and effective 
reducing significantly the incidence of peri-procedural MI.
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